Switch to:
Also traded in: Germany, Switzerland, UK

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash-to-Debt 0.12
BDX's Cash-to-Debt is ranked lower than
92% of the 172 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.62 vs. BDX: 0.12 )
Ranked among companies with meaningful Cash-to-Debt only.
BDX' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.04  Med: 0.52 Max: 1.03
Current: 0.12
0.04
1.03
Equity-to-Asset 0.31
BDX's Equity-to-Asset is ranked lower than
83% of the 168 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 0.59 vs. BDX: 0.31 )
Ranked among companies with meaningful Equity-to-Asset only.
BDX' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.25  Med: 0.48 Max: 0.63
Current: 0.31
0.25
0.63
Interest Coverage 4.89
BDX's Interest Coverage is ranked lower than
84% of the 154 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 39.88 vs. BDX: 4.89 )
Ranked among companies with meaningful Interest Coverage only.
BDX' s Interest Coverage Range Over the Past 10 Years
Min: 2.89  Med: 15.87 Max: 42.29
Current: 4.89
2.89
42.29
Piotroski F-Score: 6
Altman Z-Score: 2.96
Beneish M-Score: -2.70
WACC vs ROIC
8.31%
9.86%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating Margin % 15.21
BDX's Operating Margin % is ranked higher than
78% of the 171 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.65 vs. BDX: 15.21 )
Ranked among companies with meaningful Operating Margin % only.
BDX' s Operating Margin % Range Over the Past 10 Years
Min: 10.45  Med: 19.61 Max: 22.75
Current: 15.21
10.45
22.75
Net Margin % 10.53
BDX's Net Margin % is ranked higher than
73% of the 171 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.23 vs. BDX: 10.53 )
Ranked among companies with meaningful Net Margin % only.
BDX' s Net Margin % Range Over the Past 10 Years
Min: 6.76  Med: 15.56 Max: 18.49
Current: 10.53
6.76
18.49
ROE % 17.15
BDX's ROE % is ranked higher than
84% of the 164 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.98 vs. BDX: 17.15 )
Ranked among companies with meaningful ROE % only.
BDX' s ROE % Range Over the Past 10 Years
Min: 11.38  Med: 24.34 Max: 28.17
Current: 17.15
11.38
28.17
ROA % 5.10
BDX's ROA % is ranked higher than
62% of the 173 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.97 vs. BDX: 5.10 )
Ranked among companies with meaningful ROA % only.
BDX' s ROA % Range Over the Past 10 Years
Min: 3.57  Med: 11.79 Max: 14.79
Current: 5.1
3.57
14.79
ROC (Joel Greenblatt) % 35.48
BDX's ROC (Joel Greenblatt) % is ranked higher than
79% of the 171 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 10.87 vs. BDX: 35.48 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
BDX' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 21.71  Med: 35.48 Max: 40.37
Current: 35.48
21.71
40.37
3-Year Revenue Growth Rate 12.40
BDX's 3-Year Revenue Growth Rate is ranked higher than
81% of the 147 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.20 vs. BDX: 12.40 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
BDX' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 4.4  Med: 9.2 Max: 12.4
Current: 12.4
4.4
12.4
3-Year EBITDA Growth Rate 8.50
BDX's 3-Year EBITDA Growth Rate is ranked higher than
57% of the 123 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 5.70 vs. BDX: 8.50 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
BDX' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -1.6  Med: 9.1 Max: 15.7
Current: 8.5
-1.6
15.7
3-Year EPS without NRI Growth Rate -1.30
BDX's 3-Year EPS without NRI Growth Rate is ranked lower than
61% of the 119 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 5.50 vs. BDX: -1.30 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
BDX' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -14.2  Med: 11.4 Max: 21.9
Current: -1.3
-14.2
21.9
GuruFocus has detected 7 Warning Signs with Becton, Dickinson and Co $BDX.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» BDX's 10-Y Financials

Financials (Next Earnings Date: 2017-05-02 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q1 2016

BDX Guru Trades in Q1 2016

Paul Tudor Jones 2,300 sh (New)
Ray Dalio 10,937 sh (+115.76%)
T Rowe Price Equity Income Fund 732,099 sh (+104.61%)
First Eagle Investment 1,389,002 sh (+1.15%)
Dodge & Cox 14,930 sh (+1.01%)
Tom Gayner 9,000 sh (unchged)
Jeff Auxier 26,225 sh (unchged)
Pioneer Investments 931,609 sh (-2.27%)
Vanguard Health Care Fund 2,703,387 sh (-7.97%)
Mario Gabelli 191,090 sh (-11.10%)
Mairs and Power 4,584 sh (-11.57%)
Robert Olstein 54,000 sh (-16.92%)
Jeremy Grantham 602,775 sh (-19.60%)
Jim Simons 754,966 sh (-37.47%)
Ken Fisher 1,473 sh (-47.64%)
John Hussman 25,000 sh (-50.00%)
Joel Greenblatt 19,575 sh (-75.23%)
» More
Q2 2016

BDX Guru Trades in Q2 2016

Louis Moore Bacon 2,163 sh (New)
Paul Tudor Jones 3,201 sh (+39.17%)
Jeremy Grantham 709,700 sh (+17.74%)
T Rowe Price Equity Income Fund 860,000 sh (+17.47%)
Mairs and Power 4,703 sh (+2.60%)
Tom Gayner 9,000 sh (unchged)
Jeff Auxier 26,225 sh (unchged)
John Hussman 25,000 sh (unchged)
Pioneer Investments 917,916 sh (-1.47%)
Joel Greenblatt 18,713 sh (-4.40%)
Ken Fisher 1,395 sh (-5.30%)
Dodge & Cox 13,830 sh (-7.37%)
Mario Gabelli 162,864 sh (-14.77%)
Robert Olstein 46,000 sh (-14.81%)
Vanguard Health Care Fund 1,868,387 sh (-30.89%)
Ray Dalio 3,737 sh (-65.83%)
First Eagle Investment 390,407 sh (-71.89%)
Jim Simons 119,010 sh (-84.24%)
» More
Q3 2016

BDX Guru Trades in Q3 2016

Ray Dalio 5,000 sh (+33.80%)
Louis Moore Bacon 2,579 sh (+19.23%)
Mairs and Power 5,378 sh (+14.35%)
T Rowe Price Equity Income Fund 970,000 sh (+12.79%)
Jeremy Grantham 745,800 sh (+5.09%)
Tom Gayner 9,000 sh (unchged)
Dodge & Cox 13,830 sh (unchged)
Jeff Auxier 26,225 sh (unchged)
John Hussman Sold Out
First Eagle Investment Sold Out
Jim Simons Sold Out
Paul Tudor Jones Sold Out
Joel Greenblatt Sold Out
Ken Fisher 1,394 sh (-0.07%)
Pioneer Investments 874,062 sh (-4.78%)
Mario Gabelli 135,909 sh (-16.55%)
Robert Olstein 36,100 sh (-21.52%)
Vanguard Health Care Fund 1,301,633 sh (-30.33%)
» More
Q4 2016

BDX Guru Trades in Q4 2016

Jim Simons 336,851 sh (New)
Ray Dalio 29,515 sh (+490.30%)
Ken Fisher 1,760 sh (+26.26%)
Jeremy Grantham 764,568 sh (+2.52%)
T Rowe Price Equity Income Fund 984,000 sh (+1.44%)
Robert Olstein 36,100 sh (unchged)
Tom Gayner 9,000 sh (unchged)
Jeff Auxier 26,225 sh (unchged)
Dodge & Cox 13,830 sh (unchged)
Mairs and Power 4,778 sh (-11.16%)
Mario Gabelli 118,584 sh (-12.75%)
Vanguard Health Care Fund 1,042,273 sh (-19.93%)
Pioneer Investments 265,646 sh (-69.61%)
» More
» Details

Insider Trades

Latest Guru Trades with BDX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Instruments & Equipment » Medical Instruments & Supplies    NAICS: 339112    SIC: 3841
Compare:NYSE:BAX, OTCPK:ESLOY, NAS:ILMN, NYSE:BCR, OTCPK:CLPBY, NAS:XRAY, OTCPK:OCPNY, NYSE:MTD, NYSE:WAT, OTCPK:TRUMF, NAS:HOLX, NYSE:RMD, NYSE:COO, OTCPK:SAUHY, NYSE:WST, NYSE:STE, NYSE:HRC, OTCPK:GNGBY, NYSE:CMD, NAS:ICUI » details
Traded in other countries:BOX.Germany, BDX.Switzerland, 0R19.UK,
Becton Dickinson & Co is a medical technology company, engaged in the manufacture and sale of medical devices, instrument systems and reagents used by healthcare institutions, life science researchers, general public and clinical laboratories.

Becton Dickinson is the world's largest manufacturer and distributor of medical surgical products, such as needles, syringes, and sharps-disposal units. The company also manufactures diagnostic instruments and reagents, as well as flow cytometry and cell-imaging systems. International revenue accounts for 60% of the company's business. With CareFusion, BD has entered into medical systems (such as infusion pumps, ventilators, and respirators), as well as procedural solutions businesses.

Ratios

vs
industry
vs
history
PE Ratio 30.54
BDX's PE Ratio is ranked higher than
51% of the 139 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 30.61 vs. BDX: 30.54 )
Ranked among companies with meaningful PE Ratio only.
BDX' s PE Ratio Range Over the Past 10 Years
Min: 10.27  Med: 19.46 Max: 47.83
Current: 30.54
10.27
47.83
Forward PE Ratio 19.49
BDX's Forward PE Ratio is ranked higher than
82% of the 40 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 24.75 vs. BDX: 19.49 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 30.54
BDX's PE Ratio without NRI is ranked higher than
52% of the 130 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 30.85 vs. BDX: 30.54 )
Ranked among companies with meaningful PE Ratio without NRI only.
BDX' s PE Ratio without NRI Range Over the Past 10 Years
Min: 13.02  Med: 20.98 Max: 47.83
Current: 30.54
13.02
47.83
Price-to-Owner-Earnings 25.32
BDX's Price-to-Owner-Earnings is ranked higher than
59% of the 80 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 29.68 vs. BDX: 25.32 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
BDX' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 10.59  Med: 17.91 Max: 38.44
Current: 25.32
10.59
38.44
PB Ratio 5.17
BDX's PB Ratio is ranked lower than
70% of the 188 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.38 vs. BDX: 5.17 )
Ranked among companies with meaningful PB Ratio only.
BDX' s PB Ratio Range Over the Past 10 Years
Min: 2.96  Med: 4.11 Max: 5.6
Current: 5.17
2.96
5.6
PS Ratio 3.22
BDX's PS Ratio is ranked lower than
55% of the 187 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.85 vs. BDX: 3.22 )
Ranked among companies with meaningful PS Ratio only.
BDX' s PS Ratio Range Over the Past 10 Years
Min: 2  Med: 2.73 Max: 3.54
Current: 3.22
2
3.54
Price-to-Free-Cash-Flow 23.29
BDX's Price-to-Free-Cash-Flow is ranked higher than
66% of the 76 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 30.12 vs. BDX: 23.29 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
BDX' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 13.46  Med: 19.76 Max: 35.11
Current: 23.29
13.46
35.11
Price-to-Operating-Cash-Flow 16.57
BDX's Price-to-Operating-Cash-Flow is ranked higher than
55% of the 97 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 18.55 vs. BDX: 16.57 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
BDX' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 8.76  Med: 12.51 Max: 19.45
Current: 16.57
8.76
19.45
EV-to-EBIT 25.92
BDX's EV-to-EBIT is ranked lower than
61% of the 153 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 23.23 vs. BDX: 25.92 )
Ranked among companies with meaningful EV-to-EBIT only.
BDX' s EV-to-EBIT Range Over the Past 10 Years
Min: 9.7  Med: 14.35 Max: 40.4
Current: 25.92
9.7
40.4
EV-to-EBITDA 16.44
BDX's EV-to-EBITDA is ranked higher than
54% of the 165 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 16.75 vs. BDX: 16.44 )
Ranked among companies with meaningful EV-to-EBITDA only.
BDX' s EV-to-EBITDA Range Over the Past 10 Years
Min: 7.5  Med: 10.75 Max: 22.6
Current: 16.44
7.5
22.6
PEG Ratio 10.17
BDX's PEG Ratio is ranked lower than
95% of the 55 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.82 vs. BDX: 10.17 )
Ranked among companies with meaningful PEG Ratio only.
BDX' s PEG Ratio Range Over the Past 10 Years
Min: 0.92  Med: 1.8 Max: 24.28
Current: 10.17
0.92
24.28
Shiller PE Ratio 33.07
BDX's Shiller PE Ratio is ranked higher than
65% of the 46 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 43.77 vs. BDX: 33.07 )
Ranked among companies with meaningful Shiller PE Ratio only.
BDX' s Shiller PE Ratio Range Over the Past 10 Years
Min: 17.07  Med: 24.33 Max: 39.83
Current: 33.07
17.07
39.83
Current Ratio 1.14
BDX's Current Ratio is ranked lower than
85% of the 168 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.40 vs. BDX: 1.14 )
Ranked among companies with meaningful Current Ratio only.
BDX' s Current Ratio Range Over the Past 10 Years
Min: 1.14  Med: 2.12 Max: 5.82
Current: 1.14
1.14
5.82
Quick Ratio 0.76
BDX's Quick Ratio is ranked lower than
87% of the 168 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.64 vs. BDX: 0.76 )
Ranked among companies with meaningful Quick Ratio only.
BDX' s Quick Ratio Range Over the Past 10 Years
Min: 0.7  Med: 1.47 Max: 5.1
Current: 0.76
0.7
5.1
Days Inventory 103.78
BDX's Days Inventory is ranked higher than
66% of the 158 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 126.59 vs. BDX: 103.78 )
Ranked among companies with meaningful Days Inventory only.
BDX' s Days Inventory Range Over the Past 10 Years
Min: 103.39  Med: 120.58 Max: 127.55
Current: 103.78
103.39
127.55
Days Sales Outstanding 44.62
BDX's Days Sales Outstanding is ranked higher than
85% of the 142 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 61.07 vs. BDX: 44.62 )
Ranked among companies with meaningful Days Sales Outstanding only.
BDX' s Days Sales Outstanding Range Over the Past 10 Years
Min: 44.62  Med: 58.29 Max: 62.16
Current: 44.62
44.62
62.16
Days Payable 38.02
BDX's Days Payable is ranked lower than
67% of the 129 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 49.88 vs. BDX: 38.02 )
Ranked among companies with meaningful Days Payable only.
BDX' s Days Payable Range Over the Past 10 Years
Min: 27.63  Med: 32.87 Max: 41.22
Current: 38.02
27.63
41.22

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield % 1.51
BDX's Dividend Yield % is ranked higher than
63% of the 143 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.25 vs. BDX: 1.51 )
Ranked among companies with meaningful Dividend Yield % only.
BDX' s Dividend Yield % Range Over the Past 10 Years
Min: 1.12  Med: 1.77 Max: 2.44
Current: 1.51
1.12
2.44
Dividend Payout Ratio 0.45
BDX's Dividend Payout Ratio is ranked lower than
69% of the 85 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 0.30 vs. BDX: 0.45 )
Ranked among companies with meaningful Dividend Payout Ratio only.
BDX' s Dividend Payout Ratio Range Over the Past 10 Years
Min: 0.26  Med: 0.33 Max: 0.72
Current: 0.45
0.26
0.72
3-Year Dividend Growth Rate 10.10
BDX's 3-Year Dividend Growth Rate is ranked higher than
52% of the 63 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 10.10 vs. BDX: 10.10 )
Ranked among companies with meaningful 3-Year Dividend Growth Rate only.
BDX' s 3-Year Dividend Growth Rate Range Over the Past 10 Years
Min: 2.6  Med: 12.5 Max: 29.1
Current: 10.1
2.6
29.1
Forward Dividend Yield % 1.59
BDX's Forward Dividend Yield % is ranked higher than
63% of the 144 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.40 vs. BDX: 1.59 )
Ranked among companies with meaningful Forward Dividend Yield % only.
N/A
5-Year Yield-on-Cost % 2.43
BDX's 5-Year Yield-on-Cost % is ranked higher than
65% of the 173 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.86 vs. BDX: 2.43 )
Ranked among companies with meaningful 5-Year Yield-on-Cost % only.
BDX' s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 1.8  Med: 2.85 Max: 3.93
Current: 2.43
1.8
3.93
3-Year Average Share Buyback Ratio -3.20
BDX's 3-Year Average Share Buyback Ratio is ranked lower than
53% of the 118 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: -2.70 vs. BDX: -3.20 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
BDX' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -3.2  Med: 0.8 Max: 6
Current: -3.2
-3.2
6

Valuation & Return

vs
industry
vs
history
Price-to-Intrinsic-Value-Projected-FCF 1.90
BDX's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
56% of the 90 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.04 vs. BDX: 1.90 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
BDX' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 0.99  Med: 1.47 Max: 3.81
Current: 1.9
0.99
3.81
Price-to-Intrinsic-Value-DCF (Earnings Based) 2.85
BDX's Price-to-Intrinsic-Value-DCF (Earnings Based) is ranked lower than
64% of the 28 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.07 vs. BDX: 2.85 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-DCF (Earnings Based) only.
N/A
Price-to-Median-PS-Value 1.18
BDX's Price-to-Median-PS-Value is ranked lower than
53% of the 165 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.14 vs. BDX: 1.18 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
BDX' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.7  Med: 0.96 Max: 1.29
Current: 1.18
0.7
1.29
Earnings Yield (Greenblatt) % 3.86
BDX's Earnings Yield (Greenblatt) % is ranked higher than
61% of the 230 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.20 vs. BDX: 3.86 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
BDX' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 2.5  Med: 6.95 Max: 10.4
Current: 3.86
2.5
10.4
Forward Rate of Return (Yacktman) % 7.60
BDX's Forward Rate of Return (Yacktman) % is ranked lower than
58% of the 90 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 8.56 vs. BDX: 7.60 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
BDX' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: 5.3  Med: 14.6 Max: 19.6
Current: 7.6
5.3
19.6

More Statistics

Revenue (TTM) (Mil) $12,418
EPS (TTM) $ 6.02
Beta1.01
Short Percentage of Float1.57%
52-Week Range $147.74 - 186.11
Shares Outstanding (Mil)212.83

Analyst Estimate

Sep17 Sep18 Sep19
Revenue (Mil $) 12,092 12,666 13,112
EPS ($) 9.41 10.36 11.04
EPS without NRI ($) 9.41 10.36 11.04
EPS Growth Rate
(Future 3Y To 5Y Estimate)
9.60%
Dividends per Share ($) 2.81 3.02 3.51
» More Articles for BDX

Headlines

Articles On GuruFocus.com
Dividend Aristocrats: Medtronic vs. Becton, Dickinson & Company Mar 19 2017 
T Rowe Price Keeps Buying Exelon, Pepsi, Others Feb 28 2017 
5 Stocks to Avoid - January 2017 Jan 14 2017 
Top 7 Dividend Health Care Stocks Jan 05 2017 
The 10 Best Dividend Aristocrats for 2017 and Beyond Dec 23 2016 
Becton Dickinson Lifts Dividend by 11% Nov 30 2016 
A Growth Stock in the Land of Value Stocks? Nov 30 2016 
Dividend Aristocrats in Focus Part 26: Becton, Dickinson and Co. Nov 02 2016 
Numerous Companies Reach Yearly Highs Oct 03 2016 
The 10 Best Dividend Aristocrats Aug 15 2016 

More From Other Websites
Dividend Aristocrats: Medtronic vs. Becton, Dickinson & Company Mar 19 2017
The Zacks Analyst Blog Highlights: JPMorgan, Caterpillar, Broadcom, Mondelez and Becton Dickinson Mar 06 2017
Is Becton, Dickinson a Cure for a Sick Portfolio? Mar 03 2017
Pyxis™ ES System to Help U.S. Department of Defense Advance Medication Safety and Patient Care Mar 01 2017
BD To Present At Inaugural CECP CEO Investor Forum Feb 22 2017
BD Veritor™ System Meets FDA's New Performance Requirements for Rapid Influenza Antigen Detection... Feb 22 2017
BD Partnership Honored by U.S. Chamber of Commerce Foundation at the Health Means Business National... Feb 21 2017
BD Demonstrates Synchronized Technology Platform at HIMSS17 Feb 20 2017
BD to Present at Investor Healthcare Conferences Feb 17 2017
Post Earnings Coverage as Becton, Dickinson and Co.'s Revenue Grew 6.1%; Adjusted EPS Gained 19.4%... Feb 16 2017
BD Initiates New Industry Alliance To Combat Rising Opioid Crisis Feb 16 2017
Becton, Dickinson Launches BD Resolve Early Access Program Feb 14 2017
BD Announces Early Access Program for BD Resolve™ Single-Cell Analysis Platform Feb 13 2017
BECTON DICKINSON & CO Financials Feb 08 2017
ETFs with exposure to Becton, Dickinson & Co. : February 6, 2017 Feb 06 2017
Becton, Dickinson & Co. :BDX-US: Earnings Analysis: Q1, 2017 By the Numbers : February 3, 2017 Feb 03 2017
BECTON DICKINSON & CO Files SEC form 10-Q, Quarterly Report Feb 02 2017
Edited Transcript of BDX earnings conference call or presentation 2-Feb-17 1:00pm GMT Feb 02 2017
Becton, Dickinson (BDX) Beats on Q1 Earnings & Revenues Feb 02 2017
Becton Dickinson and Co Earnings Call scheduled for 8:00 am ET today Feb 02 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)